Pfizer Ireland marked the approval for VYNDAQEL ® (tafamidis). A once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis. This is in adult patients with cardiomyopathy (ATTR-CM). They are hosting an expert panel led symposium at the VYNDAQEL ® 61MG launch meeting.
The recently held launch meeting heard from an array of speakers including Prof. Emer Joyce, Heart Function Cardiologist at the Mater Hospital; Dr. Ross Murphy, Consultant Cardiologist at St. James’s Hospital; Dr. Pablo Garcia-Pavia Director of the Inherited Cardiac Diseases and Heart Failure Unit at Hospital Universitario Puerta de Hierro; in addition to Dr. Sarah Cuddy, Cardiologist at the Brigham and Women’s Hospital Amyloidosis Program as well as Instructor of Medicine at Harvard Medical School.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
